Skip to content
DataLookout
Menu

NCT06888479

Optimal Timing of Hepatitis B Vaccination After Transplants

StatusWithdrawn
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Withdrawn before enrolling Sponsor's reason: Insufficient execution and compliance Show 5 more changesShow less
    • Enrollment target: estimated 1500 to confirmed 0
    • Start date changed from estimate of Jun 1, 2025 to Jan 1, 2026
    • Eligibility criteria expanded, about 9 words
    • Primary completion date changed from estimate of Jun 1, 2028 to Jan 1, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: terminated, suspended or withdrawn

Endpoints

Primary

Titer of hepatitis B surface antibodies (HBsAb).
Timeframe: One month after the completion of 3 doses of hepatitis B vaccine.

Secondary (1)

HBV infection

Arms and interventions

'Early Vaccination' (low-risk)Experimental

Patients with composite immune risk score (CIRS) ≤ 2.5 and being assigned to receive 3 doses of hepatitis B vaccine at 3, 4, and 9 months after transplantation.

'Early Vaccination' (high-risk)Experimental

Patients with CIRS \> 2.5 and being assigned to receive 3 doses of hepatitis B vaccine at 3, 4, and 9 months after transplantation.

'Guideline' (low-risk)Active comparator

Patients with CIRS ≤ 2.5 and being assigned to receive 3 doses of hepatitis B vaccine at 6, 7, and 12 months after transplantation.

'Guideline' (high-risk)Active comparator

Patients with CIRS \> 2.5 and being assigned to receive 3 doses of hepatitis B vaccine at 6, 7, and 12 months after transplantation.

Biologicals: hepatitis B vaccine

Sites

1 site in 1 country

  • Institute of Hematology & Blood Diseases HospitalTianjin, Tianjin Municipality, China